No abstract

A121 effects other than bleeding and thrombosis (38.5% vs. 16.7%, p= 0.004). Patients on TSOAC had a lower [better] mean QoL summary score compared to warfarin treated patients (39.2±11.3 vs. 46.8±19.8, p= 0.01). Based on the results of the unadjusted linear regression model, patients treated with TSOAC had significantly better DASS QoL summary score (β = -7.65, 95% CI: -13.49, -1.82, p < 0.05); however, after adjusting for differences in patient groups, the effect of TSOAC on QoL became non-significant (β = 4.47, 95% CI: -5.06, 14.00, p= 0.35) ConClusions: Differences in social-demographic characteristics between patients treated with warfarin and TSOAC were observed in an inner-city population. After adjusting for patient social-demographic characteristics, TSOAC had no impact on treatment-related QoL.